Raise of Serum Concentration of Quetiapine Induced by Sodium Valproate Sustained Release Tablets and Literature Analysis

doi:10.19803/j.1672-8629.2021.10.20

Abstract

Abstract: Objective To report a severe increase in quintiapine serum concentration caused by taking emotional stabilizer sodium valproate sustained release tablets at the same time. Methods This paper analyzed one case of quintiapine concentration increase caused by sodium valproate sustained release tablets in our hospital, suggestions were put forward on rational use of drugs in clinic. Results and Conclusion The pharmaceutical care of patients taking quintiapine and sodium valproate sustained release tablets in combination should be strengthened. The effect and adverse reactions should be closely observed in clinical practice, and the blood concentration of both drugs should be monitored regularly to protect the drug safety of patients.

Key words: sodium valproate sustained release tablets, quintiapine, interaction, serum concentration

CLC Number:

R994.1

ZHUANG Hongyan, LIU Jie, DU Haixia, BAO Shuang, ZHAO Yan, HE Yue, GUO Wei. Raise of Serum Concentration of Quetiapine Induced by Sodium Valproate Sustained Release Tablets and Literature Analysis[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 986-988.

References

[1] Wei TX, Wei JH.Medical Manual for Physicians(医生专用药物手册)[M]. Zhengzhou:Henan Science and Technology Press, 2015: 758-760.
[2] Lu L. Shen YC.Psychiatry(精神病学)[M]. Beijing: People's Medical Publishing House, 2018: 871-875.
[3] Jin J, Wu FH.Clinical pharmacotherapy(临床药物治疗学)[M]. Shanghai: Shanghai Jiaotong University Press, 2015: 59-61.
[4] Zhao TH, Du H.Clinical observation of quetiapine combined with magnesium valproate sustained release tablets in the treatment of depressive episode of bipolar disorder[J]. Chinese Journal of Practical Rural Doctors(中国实用乡村医生杂志), 2016, 23(3): 66-67.
[5] Bai YZ.Effect observation of quetiapine combined with magnesium valproate in the treatment of bipolar disorder[J]. Clinical Medicine(临床医学), 2018, 12(6): 141-142.
[6] Chen SZ.Effect analysis of sodium valproate combined with quetiapine in the treatment of bipolar disorder manic episode[J].China Practical Medical(中国实用医药), 2019, 14(2): 83-84.
[7] Xu LL, Li CY, Lai KX, et al.Clinical study of quetiapine combined with valproate in the treatment of bipolar I disorder[J]. Journal of Clinical Psychosomatic Diseases(临床心身疾病杂志), 2018, 24(6): 37-40.
[8] Guan ZH, Dong RR, Bu Y.Effects of quetiapine combined with sodium valproate on depressive and manic symptoms in patients with bipolar disorder[J]. Strait Pharmaceutical Journal(海峡药学), 2019, 31(2):164-165.
[9] Vella T, Mifsud J.Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring[J]. J Pharm Pharmacol, 2014, 66(6): 747-759.
[10] Aichhorn W, Marksteiner J, Walch T, et al.Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations[J]. Int Clin Psychopharmacol, 2006, 21(2): 81-85.
[11] Liu Y, Meng LN. Improper secretion of antidiuretic hormone induced by quetiapine fumarate tablet: a case report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(2):126,128.
[12] Wang CZ.Efficacy and safety analysis of quetiapine in the treatment of acute excitability in patients with schizophrenia[J]. Clinical Research and Practice(临床医学研究与实践),2016, 1(13): 41-42.
[13] DeVane CL, Nemeroff BC. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic[J]. Clin Pharmacokinet, 2001, 40: 509-522.
[14] Bakken GV, Molden E, Knutsen K, et al.Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro[J]. Drug Metab Dispos, 2012, 40(9): 1778-1784.
[15] Wen X, Wang JS, Kivistö KT, et al.In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)[J]. Br J Clin Pharmacol, 2001, 52(5): 547-553.
[16] Van der Weide K, Van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients[J]. J Clin Psychopharmacol, 2014, 34(2): 256-260.
[17] Bai LD, Li WS, Cui KY, et al.Advances in genomics of quetiapine[J]. Medical frontier(医学前沿), 2016, 29(3): 206-209.
[18] Liu HM, Lin ZG, Ren JJ, et al.Preliminary exploration on reference range of serum quetiapine fumarate concentration[J]. World Clinical Drugs(世界临床药物),2012, 33(10): 612-615.
[19] Wang SY, Zeng XY, Xie HS, et al.Study on the influencing factors of serum concentration of quetiapine[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine(深圳中西医结合杂志), 2019, 29(10): 13-15.
[20] Tan XY, Li J.A case report on the rhabdomyolysis caused by the interaction of simvastatin[J]. Shanghai Medical & Pharmaceutical Journal(上海医药),2015, 36(13): 68-70.